首页 > 最新文献

Advanced Chinese Medicine最新文献

英文 中文
Expert consensus on quality control indicators of integrative medicine in primary Sjögren's syndrome (2023 version) 原发性斯琼格伦综合征综合医学质量控制指标专家共识(2023 年版)
Pub Date : 2024-06-20 DOI: 10.1002/acm4.21
Qing-Wen Tao, Jing Luo, Tzu-Hua Wu, Jian-Ming Wang, Yuan Xu, Di-Er Jin

Treatment integrating traditional Chinese and Western medicine for primary Sjögren's syndrome (pSS) has yielded positive results and gained wide acceptance. However, the absence of standardized clinical management in certain regions has led to suboptimal outcomes in the diagnosis and treatment of pSS in China. In response, the Center for Traditional Chinese and Western Medicine at the China-Japan Friendship Hospital, in collaboration with the Beijing Association of Traditional Chinese and Western Medicine Rheumatology Professional Committee, initiated a project led by the Traditional Chinese Medicine Department of Rheumatism. The project (Beijing Association of the Integrating of Traditional and Western Medicine standardization expert consensus record number: 2021Z031A3) aims to develop a set of quality control indicators for the integrated treatment of pSS using traditional Chinese and Western medicine. Based on the 2021 version, the consensus revision incorporates seven new items, focusing on essential assessment areas for pSS patients, treatment response, and healthcare cost management. The 2023 expert consensus update seeks to enhance pSS diagnosis and treatment practices in China, offering a benchmark for medical quality control.

中西医结合治疗原发性斯约格伦综合征(pSS)取得了良好的疗效,并被广泛接受。然而,由于某些地区缺乏规范化的临床管理,导致中国的 pSS 诊断和治疗效果并不理想。为此,中日友好医院中西医结合中心与北京中西医结合风湿病专业委员会合作,启动了一个由中医风湿科牵头的项目。该项目(北京市中西医结合学会标准化专家共识备案号:2021Z031A3)旨在制定一套中西医结合治疗 pSS 的质量控制指标。在 2021 年版本的基础上,本次共识修订新增了 7 个项目,重点关注 pSS 患者的基本评估领域、治疗反应和医疗费用管理。2023年专家共识更新版旨在加强中国的pSS诊断和治疗实践,为医疗质量控制提供一个基准。
{"title":"Expert consensus on quality control indicators of integrative medicine in primary Sjögren's syndrome (2023 version)","authors":"Qing-Wen Tao,&nbsp;Jing Luo,&nbsp;Tzu-Hua Wu,&nbsp;Jian-Ming Wang,&nbsp;Yuan Xu,&nbsp;Di-Er Jin","doi":"10.1002/acm4.21","DOIUrl":"https://doi.org/10.1002/acm4.21","url":null,"abstract":"<p>Treatment integrating traditional Chinese and Western medicine for primary Sjögren's syndrome (pSS) has yielded positive results and gained wide acceptance. However, the absence of standardized clinical management in certain regions has led to suboptimal outcomes in the diagnosis and treatment of pSS in China. In response, the Center for Traditional Chinese and Western Medicine at the China-Japan Friendship Hospital, in collaboration with the Beijing Association of Traditional Chinese and Western Medicine Rheumatology Professional Committee, initiated a project led by the Traditional Chinese Medicine Department of Rheumatism. The project (Beijing Association of the Integrating of Traditional and Western Medicine standardization expert consensus record number: 2021Z031A3) aims to develop a set of quality control indicators for the integrated treatment of pSS using traditional Chinese and Western medicine. Based on the 2021 version, the consensus revision incorporates seven new items, focusing on essential assessment areas for pSS patients, treatment response, and healthcare cost management. The 2023 expert consensus update seeks to enhance pSS diagnosis and treatment practices in China, offering a benchmark for medical quality control.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 2","pages":"87-95"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.21","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141624574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of Qi-Shao-Tong-Mai-An-Shen herbal paste on coronary heart disease patients with depression and/or anxiety: Study protocol for a randomized controlled trial 芪芍通麦安神膏对伴有抑郁和/或焦虑的冠心病患者的影响:随机对照试验研究方案
Pub Date : 2024-05-12 DOI: 10.1002/acm4.12
Ying Chen, Xiang Xiao, Lin Li, Chao-Zeng Si, Hong Jiang, Ming-Jing Shao, Xiao-Yan Lu, Shu-Liang Zheng, Tian-Gu Dai, Qing He, Li Huang

Coronary heart disease (CHD) poses a significant threat to human life and well-being. The presence of psycho-cardiology diseases not only exacerbates the progression of CHD but also imposes a substantial financial burden. Consequently, there is a pressing need to prioritize the prevention and management of psycho-cardiology conditions. Given the complex adverse effects associated with antidepressants, it is imperative to investigate alternative, safer, and more efficacious early interventions for psycho-cardiology diseases. The trial will randomly divide 99 patients who meet the inclusion criteria into two groups in a ratio of 1:2. Both groups will be administered standard western medicine treatment for CHD. The Qi-Shao-Tong-Mai-An-Shen (QSTMAS) group will be treated with an additional 30 mL QSTMAS herbal paste orally twice daily for up to 12 weeks. The primary endpoints are the changes of Generalized Anxiety Disorder-7 and Patient Health Questionnaire-9 scores after the intervention for 12 weeks. The secondary endpoints include the scores of Traditional Chinese medicine syndromes, 6-min walking test, Insomnia severity index sleep scale, laboratory tests, and other examinations of both groups after the intervention for 12 weeks. The QSTMAS herbal paste exhibits potential and promise as a treatment modality for mild-to-moderate psychological disorders within the department of cardiology. The implementation of a rigorous trial design will facilitate an objective and scientific assessment of the clinical effectiveness and safety of combining QSTMAS herbal paste with standard western medicine for CHD patients with depression and/or anxiety. Trial Registration: China Clinical Trial Registry, ChiCTR2200065179. Registered 31 October 2022.

冠心病(CHD)对人类的生命和福祉构成重大威胁。心身疾病的存在不仅会加剧冠心病的恶化,还会造成巨大的经济负担。因此,迫切需要优先预防和管理心血管精神疾病。鉴于抗抑郁药的复杂不良反应,研究其他更安全、更有效的早期干预措施来治疗心血管心理疾病势在必行。该试验将把 99 名符合纳入标准的患者按 1:2 的比例随机分为两组。两组患者都将接受标准的西医治疗。芪芍通麦安神(QSTMAS)组将额外口服 30 毫升芪芍通麦安神(QSTMAS)中药糊剂,每天两次,最长治疗 12 周。主要终点是干预 12 周后广泛性焦虑症-7 和患者健康问卷-9 评分的变化。次要终点包括干预 12 周后两组患者的中医综合征评分、6 分钟步行测试、失眠严重程度指数睡眠量表、实验室检查和其他检查。QSTMAS中药贴剂作为心内科轻度至中度心理障碍的一种治疗方式,具有潜力和前景。实施严格的试验设计将有助于客观、科学地评估将 QSTMAS 中药膏与标准西药相结合治疗患有抑郁症和/或焦虑症的心脏病患者的临床有效性和安全性。试验注册:中国临床试验注册中心,ChiCTR2200065179。注册日期:2022年10月31日。
{"title":"The effect of Qi-Shao-Tong-Mai-An-Shen herbal paste on coronary heart disease patients with depression and/or anxiety: Study protocol for a randomized controlled trial","authors":"Ying Chen,&nbsp;Xiang Xiao,&nbsp;Lin Li,&nbsp;Chao-Zeng Si,&nbsp;Hong Jiang,&nbsp;Ming-Jing Shao,&nbsp;Xiao-Yan Lu,&nbsp;Shu-Liang Zheng,&nbsp;Tian-Gu Dai,&nbsp;Qing He,&nbsp;Li Huang","doi":"10.1002/acm4.12","DOIUrl":"10.1002/acm4.12","url":null,"abstract":"<p>Coronary heart disease (CHD) poses a significant threat to human life and well-being. The presence of psycho-cardiology diseases not only exacerbates the progression of CHD but also imposes a substantial financial burden. Consequently, there is a pressing need to prioritize the prevention and management of psycho-cardiology conditions. Given the complex adverse effects associated with antidepressants, it is imperative to investigate alternative, safer, and more efficacious early interventions for psycho-cardiology diseases. The trial will randomly divide 99 patients who meet the inclusion criteria into two groups in a ratio of 1:2. Both groups will be administered standard western medicine treatment for CHD. The Qi-Shao-Tong-Mai-An-Shen (QSTMAS) group will be treated with an additional 30 mL QSTMAS herbal paste orally twice daily for up to 12 weeks. The primary endpoints are the changes of Generalized Anxiety Disorder-7 and Patient Health Questionnaire-9 scores after the intervention for 12 weeks. The secondary endpoints include the scores of Traditional Chinese medicine syndromes, 6-min walking test, Insomnia severity index sleep scale, laboratory tests, and other examinations of both groups after the intervention for 12 weeks. The QSTMAS herbal paste exhibits potential and promise as a treatment modality for mild-to-moderate psychological disorders within the department of cardiology. The implementation of a rigorous trial design will facilitate an objective and scientific assessment of the clinical effectiveness and safety of combining QSTMAS herbal paste with standard western medicine for CHD patients with depression and/or anxiety. Trial Registration: China Clinical Trial Registry, ChiCTR2200065179. Registered 31 October 2022.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 2","pages":"96-104"},"PeriodicalIF":0.0,"publicationDate":"2024-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.12","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140986978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on the mechanism of Cutaneous and Respiratory Comorbidities with Chinese and Western medicine theories and research 用中西医理论研究皮肤与呼吸系统合并症的发病机制
Pub Date : 2024-03-29 DOI: 10.1002/acm4.11
Yi Liu, Wanmu Xie, Yue Yan, Baoyi Liu, Ang Li, Yue Yang, Xinzhu Zhou, Xianbo Zuo, Zhenguo Zhai, Yong Cui

In the realms of traditional Chinese medicine and Western medicine research, the skin and lungs are recognized for their integral roles in both the physiological functions and pathological mechanisms affecting the human body. These organs are not only complementary and coordinated in their physiological functions but also interact pathologically, providing feedback and influencing each other. The etiology of immune-mediated skin diseases is multifaceted, involving numerous factors beyond mere skin characteristics, often including multisystem diseases. Cutaneous and Respiratory Comorbidities denote the concurrent presence of skin and lung diseases, sharing a common pathogenic mechanism. Although research on Cutaneous and Respiratory Comorbidities has received increasing attention, the foundational theories and the specifics of related diseases remain unclear. This paper aims to elucidate the theoretical basis of both traditional Chinese and Western medicine concerning immune-mediated Cutaneous and Respiratory Comorbidities, thereby laying a groundwork for the early detection and integrated treatment of these diseases.

在传统中医和西医研究领域,皮肤和肺被认为在影响人体的生理功能和病理机制中发挥着不可或缺的作用。这两个器官不仅在生理功能上相互补充、相互协调,而且在病理上也相互作用、相互反馈、相互影响。免疫介导的皮肤病的病因是多方面的,除了单纯的皮肤特征外,还涉及许多因素,通常包括多系统疾病。皮肤和呼吸系统合并症是指皮肤和肺部疾病同时存在,具有共同的致病机制。尽管对皮肤和呼吸系统合并症的研究已受到越来越多的关注,但相关疾病的基础理论和具体情况仍不清楚。本文旨在阐明免疫介导的皮肤与呼吸系统合并症的中西医理论基础,从而为这些疾病的早期发现和综合治疗奠定基础。
{"title":"Study on the mechanism of Cutaneous and Respiratory Comorbidities with Chinese and Western medicine theories and research","authors":"Yi Liu,&nbsp;Wanmu Xie,&nbsp;Yue Yan,&nbsp;Baoyi Liu,&nbsp;Ang Li,&nbsp;Yue Yang,&nbsp;Xinzhu Zhou,&nbsp;Xianbo Zuo,&nbsp;Zhenguo Zhai,&nbsp;Yong Cui","doi":"10.1002/acm4.11","DOIUrl":"10.1002/acm4.11","url":null,"abstract":"<p>In the realms of traditional Chinese medicine and Western medicine research, the skin and lungs are recognized for their integral roles in both the physiological functions and pathological mechanisms affecting the human body. These organs are not only complementary and coordinated in their physiological functions but also interact pathologically, providing feedback and influencing each other. The etiology of immune-mediated skin diseases is multifaceted, involving numerous factors beyond mere skin characteristics, often including multisystem diseases. Cutaneous and Respiratory Comorbidities denote the concurrent presence of skin and lung diseases, sharing a common pathogenic mechanism. Although research on Cutaneous and Respiratory Comorbidities has received increasing attention, the foundational theories and the specifics of related diseases remain unclear. This paper aims to elucidate the theoretical basis of both traditional Chinese and Western medicine concerning immune-mediated Cutaneous and Respiratory Comorbidities, thereby laying a groundwork for the early detection and integrated treatment of these diseases.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"52-65"},"PeriodicalIF":0.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140365510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New approach to heart failure: Integrated traditional Chinese with Western medicine 治疗心力衰竭的新方法:中西医结合
Pub Date : 2024-03-12 DOI: 10.1002/acm4.10
Qiao Wang, Hongshuai Cao, Peizhao Li, Chunyan Li, Zaixiang Shi, Jingyi Ren

Heart failure (HF) is a major global healthcare problem leading to substantial deterioration of prognosis. The current clinical guidelines in HF have begun to emphasize the importance of traditional Chinese medicine (TCM). TCM has been utilized in clinical practice for over 2000 years and is capable of treating a variety of HF pathogenic issues. This review summarizes the classification, pathophysiology, and treatment of HF from three perspectives: Western medicine, TCM, and integrated traditional Chinese and Western medicine (ITCWM). Emphasizing the most recent evidence, this review consolidates knowledge on ITCWM treatments for HF pertaining to different TCM syndromes, including TCM decoctions, oral patent Chinese medicine, TCM injections, as well as therapies like acupuncture and moxibustion. Additionally, this review explores TCM approaches to HF prevention, such as tai chi, Baduanjin exercise, and Sanfu acupoint herbal patching. The findings of this study suggest that ITCWM holds promise for the treatment and rehabilitation of HF. However, further research is warranted to elucidate the underlying mechanisms.

心力衰竭(HF)是导致预后严重恶化的全球主要医疗问题。目前的心力衰竭临床指南已开始强调传统中医药(TCM)的重要性。中医在临床实践中的应用已有 2000 多年的历史,能够治疗各种心房颤动致病问题。本综述从三个角度总结了高血压的分类、病理生理学和治疗:本综述从西医、中医和中西医结合(ITCWM)三个角度总结了高血压的分类、病理生理学和治疗方法。本综述强调最新证据,整合了与不同中医综合征相关的中西医结合治疗高血压的知识,包括中药煎剂、口服中成药、中药注射剂以及针灸等疗法。此外,本综述还探讨了中医预防高血压的方法,如太极拳、八段锦锻炼和三伏贴敷。本研究的结果表明,ITCWM 在治疗和康复高血压方面大有可为。然而,还需要进一步的研究来阐明其潜在机制。
{"title":"New approach to heart failure: Integrated traditional Chinese with Western medicine","authors":"Qiao Wang,&nbsp;Hongshuai Cao,&nbsp;Peizhao Li,&nbsp;Chunyan Li,&nbsp;Zaixiang Shi,&nbsp;Jingyi Ren","doi":"10.1002/acm4.10","DOIUrl":"10.1002/acm4.10","url":null,"abstract":"<p>Heart failure (HF) is a major global healthcare problem leading to substantial deterioration of prognosis. The current clinical guidelines in HF have begun to emphasize the importance of traditional Chinese medicine (TCM). TCM has been utilized in clinical practice for over 2000 years and is capable of treating a variety of HF pathogenic issues. This review summarizes the classification, pathophysiology, and treatment of HF from three perspectives: Western medicine, TCM, and integrated traditional Chinese and Western medicine (ITCWM). Emphasizing the most recent evidence, this review consolidates knowledge on ITCWM treatments for HF pertaining to different TCM syndromes, including TCM decoctions, oral patent Chinese medicine, TCM injections, as well as therapies like acupuncture and moxibustion. Additionally, this review explores TCM approaches to HF prevention, such as tai chi, Baduanjin exercise, and <i>Sanfu</i> acupoint herbal patching. The findings of this study suggest that ITCWM holds promise for the treatment and rehabilitation of HF. However, further research is warranted to elucidate the underlying mechanisms.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"19-39"},"PeriodicalIF":0.0,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140249103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guiding modern traditional Chinese medicine research using the theory of state-target differentiation and treatment—Maintaining the validity of traditional Chinese medicine and creating new medical science 用国标本分治理论指导现代中医药研究--维护中医药的有效性,创造新的医学科学
Pub Date : 2024-03-04 DOI: 10.1002/acm4.8
Jiaran Lin, Jiaxing Tian, Xinyi Fang, Boxun Zhang, Yingying Yang, Yu Wei, Lisha He, Ye Lei, Bin Song, Linhua Zhao, Xiaolin Tong

As an important part of Chinese civilization, traditional Chinese medicine (TCM) has a long history and broad social foundation. In the development of modern medicine, TCM bears the responsibility of inheriting Chinese culture, while integrating with modern science and technology to continuously promote medical progress. The theory of “state-target differentiation and treatment” is an innovative model combining Chinese and Western medicine that has provided a new mindset and method for modernizing TCM. This theory not only guides the reconstruction of modern TCM diagnosis and treatment systems, but also strongly promotes the reconstruction of the modern herbal system. As an emerging bioinformatics technology, phenomics research can reveal biological processes dynamically and quantitatively, which will help “open the black box” of TCM by providing technical methods to reveal the nature of “state” and the mechanism of “state modulation” in TCM. TCM can provide a valuable clinical reference from the perspective of disease cognition, sort out phenomics information parameters systematically and uniformly, and provide more accurate and meaningful data for phenomics research. The in-depth combination of TCM and phenomics from the concept and technology will vigorously promote the development of human precision medicine. Modern TCM research guided by the theory of state-target differentiation and treatment can effectively improve the scientific basis and targetability of clinical treatments and can also initiate a breakthrough in the integration of Chinese and Western medicine, further promoting the profound communication and cooperation between Chinese and Western medicine, so as to achieve better development of medicine in the future.

中医药作为中华文明的重要组成部分,有着悠久的历史和广泛的社会基础。在现代医学发展中,中医药承担着传承中华文化的重任,同时与现代科技相结合,不断推动医学进步。"国标分型论治 "是中西医结合的创新模式,为中医药现代化提供了新思维、新方法。这一理论不仅指导了现代中医诊疗体系的重建,也有力地推动了现代中药体系的重建。表型组学研究作为一种新兴的生物信息学技术,可以动态、定量地揭示生物过程,为揭示中医 "状态 "的本质和 "状态调控 "的机制提供技术方法,有助于 "打开中医黑箱"。中医药可以从疾病认知的角度为临床提供有价值的参考,系统、统一地梳理表型组学信息参数,为表型组学研究提供更准确、更有意义的数据。中医药与表型组学从理念和技术上的深度结合,将有力推动人类精准医学的发展。以状态-靶标分型论治为指导的现代中医药研究,能有效提高临床治疗的科学性和靶向性,也能开启中西医结合的突破口,进一步促进中西医的深度交流与合作,从而实现未来医学的更好发展。
{"title":"Guiding modern traditional Chinese medicine research using the theory of state-target differentiation and treatment—Maintaining the validity of traditional Chinese medicine and creating new medical science","authors":"Jiaran Lin,&nbsp;Jiaxing Tian,&nbsp;Xinyi Fang,&nbsp;Boxun Zhang,&nbsp;Yingying Yang,&nbsp;Yu Wei,&nbsp;Lisha He,&nbsp;Ye Lei,&nbsp;Bin Song,&nbsp;Linhua Zhao,&nbsp;Xiaolin Tong","doi":"10.1002/acm4.8","DOIUrl":"10.1002/acm4.8","url":null,"abstract":"<p>As an important part of Chinese civilization, traditional Chinese medicine (TCM) has a long history and broad social foundation. In the development of modern medicine, TCM bears the responsibility of inheriting Chinese culture, while integrating with modern science and technology to continuously promote medical progress. The theory of “state-target differentiation and treatment” is an innovative model combining Chinese and Western medicine that has provided a new mindset and method for modernizing TCM. This theory not only guides the reconstruction of modern TCM diagnosis and treatment systems, but also strongly promotes the reconstruction of the modern herbal system. As an emerging bioinformatics technology, phenomics research can reveal biological processes dynamically and quantitatively, which will help “open the black box” of TCM by providing technical methods to reveal the nature of “state” and the mechanism of “state modulation” in TCM. TCM can provide a valuable clinical reference from the perspective of disease cognition, sort out phenomics information parameters systematically and uniformly, and provide more accurate and meaningful data for phenomics research. The in-depth combination of TCM and phenomics from the concept and technology will vigorously promote the development of human precision medicine. Modern TCM research guided by the theory of state-target differentiation and treatment can effectively improve the scientific basis and targetability of clinical treatments and can also initiate a breakthrough in the integration of Chinese and Western medicine, further promoting the profound communication and cooperation between Chinese and Western medicine, so as to achieve better development of medicine in the future.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"3-12"},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140266001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current traditional Chinese medicine treatments of psoriasis vulgaris 目前治疗寻常型银屑病的传统中医疗法
Pub Date : 2024-03-01 DOI: 10.1002/acm4.2
Ying Luo, Jiankun Song, Le Kuai, Qi Zheng, Mingxia Wang, Guoshu Deng, Ying Zhang, Xin Li, Ruiping Wang, Bin Li

Psoriasis is a kind of immune-mediated chronic skin disease induced by combined genetic and environmental factors. The effective and safe treatment of psoriasis has always been a challenge in dermatology clinics. Traditional Chinese medicine (TCM), an important direction for the current treatment of psoriasis, is characterized by historical significance, unique characteristics, and rich experience. In recent years, the “hemo-modulating therapy” of TCM has reached a consensus with excellent progress in the treatment of psoriasis. This paper reviews the current TCM treatments of psoriasis and discusses the possibilities for psoriasis disease management.

银屑病是一种由遗传和环境因素共同诱发的免疫介导型慢性皮肤病。如何有效、安全地治疗银屑病一直是皮肤科临床面临的难题。中医药作为当前治疗银屑病的一个重要方向,具有历史悠久、特色鲜明、经验丰富等特点。近年来,中医的 "调血疗法 "在银屑病的治疗中取得了很好的进展,达成了共识。本文回顾了目前中医治疗银屑病的方法,并探讨了银屑病疾病治疗的可能性。
{"title":"Current traditional Chinese medicine treatments of psoriasis vulgaris","authors":"Ying Luo,&nbsp;Jiankun Song,&nbsp;Le Kuai,&nbsp;Qi Zheng,&nbsp;Mingxia Wang,&nbsp;Guoshu Deng,&nbsp;Ying Zhang,&nbsp;Xin Li,&nbsp;Ruiping Wang,&nbsp;Bin Li","doi":"10.1002/acm4.2","DOIUrl":"10.1002/acm4.2","url":null,"abstract":"<p>Psoriasis is a kind of immune-mediated chronic skin disease induced by combined genetic and environmental factors. The effective and safe treatment of psoriasis has always been a challenge in dermatology clinics. Traditional Chinese medicine (TCM), an important direction for the current treatment of psoriasis, is characterized by historical significance, unique characteristics, and rich experience. In recent years, the “hemo-modulating therapy” of TCM has reached a consensus with excellent progress in the treatment of psoriasis. This paper reviews the current TCM treatments of psoriasis and discusses the possibilities for psoriasis disease management.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"13-18"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140084116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
At the beginning 开始时
Pub Date : 2024-02-26 DOI: 10.1002/acm4.9
Yong Cui, ACM Editors-in-Chief Team

Traditional Chinese Medicine (TCM) is an esteemed medical system that originated in China and has safeguarded the survival and prosperity of the Chinese nation for over three millennia. TCM stands not only as a cherished national treasure but also as a shared heritage for people worldwide. After Western medicine was introduced into China over a century ago, it sparked a fervent clash with TCM due to the cultural disparities and fundamental theoretical differences between the two. Nevertheless, amidst the debates over right and wrong, and the quest for scientific superiority between Chinese and Western medicine, it is crucial to remember that the core purpose of medicine is to heal the ailing and preserve the living, with efficacy serving as the ultimate criterion for discerning truth. Consequently, following the founding of the People's Republic of China in 1949, the Chinese government formulated a fundamental health policy, advocating for the integration, communication, and cooperative advancement of Chinese and Western medicine. Guided by this approach, China's medical and health endeavors have flourished, epitomized by their resounding triumph in combatting the COVID-19 pandemic.

In recent years, the rapid advancements of science and technology have contributed significantly to the development of modern medicine. However, despite these remarkable achievements, the current medical system still faces numerous challenges due to the complexity of human diseases. Malignant tumors, immunological disorders, rapid outbreaks of novel infectious diseases, cardiovascular diseases, and other complex conditions still pose severe challenges to human health. In light of this, TCM, though an ancient medical system, offers distinctive insights into human physiology, pathology, and natural medicine pharmacology, which hold tremendous potential for catalyzing the growth and advancement of human medicine.

As our understanding of diseases and health improves, modern medicine has gradually shifted from a micro perspective to a macro one, as exemplified by the emergence of concepts such as phenomics and integrative medicine. TCM too, evolves in tandem with current science and technology, such as with the rise of microcosmic syndrome differentiation, the combination of disease and syndrome, as well as state-targeted differentiation and treatment. Consequently, the future trajectory of human medicine lies in the development of a new medical system that integrates both macro and micro approaches.

Against this background, the National Medical Center of Integrated Chinese and Western Medicine of China-Japan Friendship Hospital and the Higher Education Press are proud to jointly announce the publication of Advanced Chinese Medicine (ACM). ACM aims to present the theoretical descriptions and research products within the framework of integrated Chinese and Western medicine to the global community. ACM aspires to serve as a platform for communicat

中医(TCM)是源于中国、备受推崇的医学体系,三千多年来一直守护着中华民族的生存与繁荣。中医药不仅是国之瑰宝,也是世界人民的共同遗产。一百多年前,西医传入中国后,由于文化差异和理论基础不同,引发了与中医的激烈碰撞。然而,在中西医是非之争、科学优劣之争中,我们必须牢记,医学的核心目的是治病救人,疗效是辨别真理的最终标准。因此,1949 年中华人民共和国成立后,中国政府制定了基本卫生政策,倡导中西医结合、交流与合作。在这一方针的指导下,中国的医疗卫生事业蓬勃发展,在抗击 COVID-19 大流行的斗争中取得了巨大胜利。然而,尽管取得了这些令人瞩目的成就,但由于人类疾病的复杂性,当前的医疗体系仍然面临着诸多挑战。恶性肿瘤、免疫性疾病、快速爆发的新型传染病、心血管疾病等复杂病症仍对人类健康构成严峻挑战。有鉴于此,中医药作为一个古老的医学体系,在人体生理、病理和天然药物药理方面具有独特的见解,在促进人类医学的发展和进步方面具有巨大的潜力。随着我们对疾病和健康认识的提高,现代医学逐渐从微观视角转向宏观视角,表型组学和整合医学等概念的出现就是例证。中医药也与当前的科学技术同步发展,如微观综合征分型、病证结合、状态靶向分型治疗等的兴起。在此背景下,中日友好医院国家中西医结合医学中心与高等教育出版社隆重推出《高级中医学》(ACM)。高级中医药》旨在向国际社会展示中西医结合框架内的理论阐述和研究成果。ACM 希望成为这两种医学体系之间交流和融合的平台,以及东西方文化交流的文化网络。在创刊号上,童小林院士介绍了以国家靶向分型论治为桥梁的中西医交流融合方法论。展望未来,《中西医结合杂志》欢迎进一步投稿,内容涵盖理论、临床和基础研究。到 2024 年初,《中西医结合杂志》将推出网络版,由 ScholarOne 作为投稿、评论和编辑交流的平台。我们尊敬的编委会致力于将《中西医结合杂志》打造成中西医结合研究的新中心,并在此过程中促进国际合作:作者声明无利益冲突。
{"title":"At the beginning","authors":"Yong Cui,&nbsp;ACM Editors-in-Chief Team","doi":"10.1002/acm4.9","DOIUrl":"10.1002/acm4.9","url":null,"abstract":"<p>Traditional Chinese Medicine (TCM) is an esteemed medical system that originated in China and has safeguarded the survival and prosperity of the Chinese nation for over three millennia. TCM stands not only as a cherished national treasure but also as a shared heritage for people worldwide. After Western medicine was introduced into China over a century ago, it sparked a fervent clash with TCM due to the cultural disparities and fundamental theoretical differences between the two. Nevertheless, amidst the debates over right and wrong, and the quest for scientific superiority between Chinese and Western medicine, it is crucial to remember that the core purpose of medicine is to heal the ailing and preserve the living, with efficacy serving as the ultimate criterion for discerning truth. Consequently, following the founding of the People's Republic of China in 1949, the Chinese government formulated a fundamental health policy, advocating for the integration, communication, and cooperative advancement of Chinese and Western medicine. Guided by this approach, China's medical and health endeavors have flourished, epitomized by their resounding triumph in combatting the COVID-19 pandemic.</p><p>In recent years, the rapid advancements of science and technology have contributed significantly to the development of modern medicine. However, despite these remarkable achievements, the current medical system still faces numerous challenges due to the complexity of human diseases. Malignant tumors, immunological disorders, rapid outbreaks of novel infectious diseases, cardiovascular diseases, and other complex conditions still pose severe challenges to human health. In light of this, TCM, though an ancient medical system, offers distinctive insights into human physiology, pathology, and natural medicine pharmacology, which hold tremendous potential for catalyzing the growth and advancement of human medicine.</p><p>As our understanding of diseases and health improves, modern medicine has gradually shifted from a micro perspective to a macro one, as exemplified by the emergence of concepts such as phenomics and integrative medicine. TCM too, evolves in tandem with current science and technology, such as with the rise of microcosmic syndrome differentiation, the combination of disease and syndrome, as well as state-targeted differentiation and treatment. Consequently, the future trajectory of human medicine lies in the development of a new medical system that integrates both macro and micro approaches.</p><p>Against this background, the National Medical Center of Integrated Chinese and Western Medicine of China-Japan Friendship Hospital and the Higher Education Press are proud to jointly announce the publication of <i>Advanced Chinese Medicine</i> (ACM). ACM aims to present the theoretical descriptions and research products within the framework of integrated Chinese and Western medicine to the global community. ACM aspires to serve as a platform for communicat","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140428987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effectiveness of Baduanjin on metabolic syndrome: An overview of systematic reviews and meta-analyses 八段锦对代谢综合征的疗效:系统回顾和荟萃分析综述
Pub Date : 2024-02-05 DOI: 10.1002/acm4.3
JingYi Zhao, Min Li, KaiLe Ma, Rui Hao, LiJuan Zhou

Objective

This meta-analysis evaluated the effects of Baduanjin on the metabolic status of individuals with metabolic syndrome (MetS). The aim was to identify effective interventions for MetS prevention and treatment.

Methods

We conducted a comprehensive search of English (PubMed, Embase, Web of Science, and Cochrane Library) and Chinese (CNKI, Wanfang, Chinese Biomedical Database, VIP) databases till August 19, 2022. Randomized controlled trials (RCTs) focusing on Baduanjin for MetS patients were included. Data were pooled and assessed using the Cochrane risk-of-bias tool. The Grades of Recommendation, Assessment, Development, and Evaluation for Systematic Reviews was used to evaluate literature quality.

Results

Eight RCTs involving 435 participants were included. Baduanjin showed significant improvements in fasting blood glucose (mean difference [MD] = −0.41, 95% confidence interval [CI] [−0.22, −0.61], p < 0.0001) and glycated hemoglobin levels (MD = −0.99, 95% CI [−0.38, −1.60], p < 0.00001). Waist-to-hip ratio (MD = −0.04, 95% CI [−0.03, −0.06], p = 0.002), body mass index (MD = −1.60, 95% CI [−0.10, −3.10], p = 0.04), fasting insulin (MD = −4.82, 95% CI [−0.15, −8.59], p = 0.01), systolic blood pressure (MD = −7.16, 95% CI [−5.16, −9.17], p < 0.00001), diastolic blood pressure (MD = −3.43, 95% CI [−0.62, −6.24], p = 0.02), total cholesterol (MD = −0.48, 95% CI [−0.10, −0.85], p = 0.01), triglycerides (MD = −0.39, 95% CI [−0.14, −0.64], p = 0.003), and low-density lipoprotein cholesterol (MD = −0.52, 95% CI [−0.10, −0.94], p = 0.01) also significantly improved. No adverse events were reported. Literature quality ranged from very low to moderate.

Conclusions

Baduanjin effectively improves metabolic status in individuals with MetS, including blood glucose, lipid profile, obesity-related indicators, insulin levels, and blood pressure. However, the overall literature quality is moderate to low. Further rigorous RCTs are needed to explore Baduanjin's effects on MetS, considering intervention methods, content, and research methodologies.

这项荟萃分析评估了八段锦对代谢综合征(MetS)患者代谢状况的影响。截至 2022 年 8 月 19 日,我们对英文(PubMed、Embase、Web of Science 和 Cochrane Library)和中文(CNKI、万方、中国生物医学数据库、VIP)数据库进行了全面检索。纳入的随机对照试验(RCT)均以八段锦治疗 MetS 患者为研究对象。使用 Cochrane 偏倚风险工具对数据进行汇总和评估。采用系统综述的推荐、评估、开发和评价等级来评估文献质量。巴杜安金显著改善了空腹血糖(平均差 [MD] = -0.41,95% 置信区间 [CI] [-0.22, -0.61],p < 0.0001)和糖化血红蛋白水平(MD = -0.99,95% CI [-0.38, -1.60], p < 0.00001)。腰臀比(MD = -0.04,95% CI [-0.03,-0.06],P =0.002)、体重指数(MD =-1.60,95% CI [-0.10,-3.10],P =0.04)、空腹胰岛素(MD = -4.82,95% CI [-0.10,-3.10],P =0.0001)和糖化血红蛋白水平(MD = -0.99,95% CI [-0.38,-1.60],P <0.00001)。82,95% CI [-0.15,-8.59],P = 0.01)、收缩压(MD = -7.16,95% CI [-5.16,-9.17],P <0.00001)、舒张压(MD = -3。43,95% CI [-0.62,-6.24],p = 0.02)、总胆固醇(MD = -0.48,95% CI [-0.10,-0.85],p = 0.01)、甘油三酯(MD = -0.39,95% CI [-0.14,-0.64],p = 0.003)和低密度脂蛋白胆固醇(MD = -0.52,95% CI [-0.10,-0.94],p = 0.01)也显著改善。无不良事件报告。文献质量从很低到中等不等。巴豆神能有效改善 MetS 患者的代谢状况,包括血糖、血脂、肥胖相关指标、胰岛素水平和血压。然而,总体文献质量为中低水平。考虑到干预方法、内容和研究方法,还需要进一步进行严格的 RCT 研究,以探讨八段锦对 MetS 的影响。
{"title":"The effectiveness of Baduanjin on metabolic syndrome: An overview of systematic reviews and meta-analyses","authors":"JingYi Zhao,&nbsp;Min Li,&nbsp;KaiLe Ma,&nbsp;Rui Hao,&nbsp;LiJuan Zhou","doi":"10.1002/acm4.3","DOIUrl":"10.1002/acm4.3","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This meta-analysis evaluated the effects of Baduanjin on the metabolic status of individuals with metabolic syndrome (MetS). The aim was to identify effective interventions for MetS prevention and treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a comprehensive search of English (PubMed, Embase, Web of Science, and Cochrane Library) and Chinese (CNKI, Wanfang, Chinese Biomedical Database, VIP) databases till August 19, 2022. Randomized controlled trials (RCTs) focusing on Baduanjin for MetS patients were included. Data were pooled and assessed using the Cochrane risk-of-bias tool. The Grades of Recommendation, Assessment, Development, and Evaluation for Systematic Reviews was used to evaluate literature quality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eight RCTs involving 435 participants were included. Baduanjin showed significant improvements in fasting blood glucose (mean difference [MD] = −0.41, 95% confidence interval [CI] [−0.22, −0.61], <i>p</i> &lt; 0.0001) and glycated hemoglobin levels (MD = −0.99, 95% CI [−0.38, −1.60], <i>p</i> &lt; 0.00001). Waist-to-hip ratio (MD = −0.04, 95% CI [−0.03, −0.06], <i>p</i> = 0.002), body mass index (MD = −1.60, 95% CI [−0.10, −3.10], <i>p</i> = 0.04), fasting insulin (MD = −4.82, 95% CI [−0.15, −8.59], <i>p</i> = 0.01), systolic blood pressure (MD = −7.16, 95% CI [−5.16, −9.17], <i>p</i> &lt; 0.00001), diastolic blood pressure (MD = −3.43, 95% CI [−0.62, −6.24], <i>p</i> = 0.02), total cholesterol (MD = −0.48, 95% CI [−0.10, −0.85], <i>p</i> = 0.01), triglycerides (MD = −0.39, 95% CI [−0.14, −0.64], <i>p</i> = 0.003), and low-density lipoprotein cholesterol (MD = −0.52, 95% CI [−0.10, −0.94], <i>p</i> = 0.01) also significantly improved. No adverse events were reported. Literature quality ranged from very low to moderate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Baduanjin effectively improves metabolic status in individuals with MetS, including blood glucose, lipid profile, obesity-related indicators, insulin levels, and blood pressure. However, the overall literature quality is moderate to low. Further rigorous RCTs are needed to explore Baduanjin's effects on MetS, considering intervention methods, content, and research methodologies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"66-78"},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139802928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effectiveness of Baduanjin on metabolic syndrome: An overview of systematic reviews and meta‐analyses 八段锦对代谢综合征的疗效:系统回顾和荟萃分析综述
Pub Date : 2024-02-05 DOI: 10.1002/acm4.3
J. Zhao, Min Li, Kaile Ma, Rui Hao, Lijuan Zhou
This meta‐analysis evaluated the effects of Baduanjin on the metabolic status of individuals with metabolic syndrome (MetS). The aim was to identify effective interventions for MetS prevention and treatment.We conducted a comprehensive search of English (PubMed, Embase, Web of Science, and Cochrane Library) and Chinese (CNKI, Wanfang, Chinese Biomedical Database, VIP) databases till August 19, 2022. Randomized controlled trials (RCTs) focusing on Baduanjin for MetS patients were included. Data were pooled and assessed using the Cochrane risk‐of‐bias tool. The Grades of Recommendation, Assessment, Development, and Evaluation for Systematic Reviews was used to evaluate literature quality.Eight RCTs involving 435 participants were included. Baduanjin showed significant improvements in fasting blood glucose (mean difference [MD] = −0.41, 95% confidence interval [CI] [−0.22, −0.61], p < 0.0001) and glycated hemoglobin levels (MD = −0.99, 95% CI [−0.38, −1.60], p < 0.00001). Waist‐to‐hip ratio (MD = −0.04, 95% CI [−0.03, −0.06], p = 0.002), body mass index (MD = −1.60, 95% CI [−0.10, −3.10], p = 0.04), fasting insulin (MD = −4.82, 95% CI [−0.15, −8.59], p = 0.01), systolic blood pressure (MD = −7.16, 95% CI [−5.16, −9.17], p < 0.00001), diastolic blood pressure (MD = −3.43, 95% CI [−0.62, −6.24], p = 0.02), total cholesterol (MD = −0.48, 95% CI [−0.10, −0.85], p = 0.01), triglycerides (MD = −0.39, 95% CI [−0.14, −0.64], p = 0.003), and low‐density lipoprotein cholesterol (MD = −0.52, 95% CI [−0.10, −0.94], p = 0.01) also significantly improved. No adverse events were reported. Literature quality ranged from very low to moderate.Baduanjin effectively improves metabolic status in individuals with MetS, including blood glucose, lipid profile, obesity‐related indicators, insulin levels, and blood pressure. However, the overall literature quality is moderate to low. Further rigorous RCTs are needed to explore Baduanjin's effects on MetS, considering intervention methods, content, and research methodologies.
这项荟萃分析评估了八段锦对代谢综合征(MetS)患者代谢状况的影响。截至 2022 年 8 月 19 日,我们对英文(PubMed、Embase、Web of Science 和 Cochrane Library)和中文(CNKI、万方、中国生物医学数据库、VIP)数据库进行了全面检索。纳入的随机对照试验(RCT)均以八段锦治疗 MetS 患者为研究对象。使用 Cochrane 偏倚风险工具对数据进行汇总和评估。采用系统综述的推荐、评估、开发和评价等级来评估文献质量。巴杜安金显著改善了空腹血糖(平均差 [MD] = -0.41,95% 置信区间 [CI] [-0.22, -0.61],p < 0.0001)和糖化血红蛋白水平(MD = -0.99,95% CI [-0.38, -1.60], p < 0.00001)。腰臀比(MD = -0.04,95% CI [-0.03,-0.06],P =0.002)、体重指数(MD =-1.60,95% CI [-0.10,-3.10],P =0.04)、空腹胰岛素(MD = -4.82,95% CI [-0.10,-3.10],P =0.0001)和糖化血红蛋白水平(MD = -0.99,95% CI [-0.38,-1.60],P <0.00001)。82,95% CI [-0.15,-8.59],P = 0.01)、收缩压(MD = -7.16,95% CI [-5.16,-9.17],P <0.00001)、舒张压(MD = -3。43,95% CI [-0.62,-6.24],p = 0.02)、总胆固醇(MD = -0.48,95% CI [-0.10,-0.85],p = 0.01)、甘油三酯(MD = -0.39,95% CI [-0.14,-0.64],p = 0.003)和低密度脂蛋白胆固醇(MD = -0.52,95% CI [-0.10,-0.94],p = 0.01)也显著改善。无不良事件报告。文献质量从很低到中等不等。巴豆神能有效改善 MetS 患者的代谢状况,包括血糖、血脂、肥胖相关指标、胰岛素水平和血压。然而,总体文献质量为中低水平。考虑到干预方法、内容和研究方法,还需要进一步进行严格的 RCT 研究,以探讨八段锦对 MetS 的影响。
{"title":"The effectiveness of Baduanjin on metabolic syndrome: An overview of systematic reviews and meta‐analyses","authors":"J. Zhao, Min Li, Kaile Ma, Rui Hao, Lijuan Zhou","doi":"10.1002/acm4.3","DOIUrl":"https://doi.org/10.1002/acm4.3","url":null,"abstract":"This meta‐analysis evaluated the effects of Baduanjin on the metabolic status of individuals with metabolic syndrome (MetS). The aim was to identify effective interventions for MetS prevention and treatment.We conducted a comprehensive search of English (PubMed, Embase, Web of Science, and Cochrane Library) and Chinese (CNKI, Wanfang, Chinese Biomedical Database, VIP) databases till August 19, 2022. Randomized controlled trials (RCTs) focusing on Baduanjin for MetS patients were included. Data were pooled and assessed using the Cochrane risk‐of‐bias tool. The Grades of Recommendation, Assessment, Development, and Evaluation for Systematic Reviews was used to evaluate literature quality.Eight RCTs involving 435 participants were included. Baduanjin showed significant improvements in fasting blood glucose (mean difference [MD] = −0.41, 95% confidence interval [CI] [−0.22, −0.61], p < 0.0001) and glycated hemoglobin levels (MD = −0.99, 95% CI [−0.38, −1.60], p < 0.00001). Waist‐to‐hip ratio (MD = −0.04, 95% CI [−0.03, −0.06], p = 0.002), body mass index (MD = −1.60, 95% CI [−0.10, −3.10], p = 0.04), fasting insulin (MD = −4.82, 95% CI [−0.15, −8.59], p = 0.01), systolic blood pressure (MD = −7.16, 95% CI [−5.16, −9.17], p < 0.00001), diastolic blood pressure (MD = −3.43, 95% CI [−0.62, −6.24], p = 0.02), total cholesterol (MD = −0.48, 95% CI [−0.10, −0.85], p = 0.01), triglycerides (MD = −0.39, 95% CI [−0.14, −0.64], p = 0.003), and low‐density lipoprotein cholesterol (MD = −0.52, 95% CI [−0.10, −0.94], p = 0.01) also significantly improved. No adverse events were reported. Literature quality ranged from very low to moderate.Baduanjin effectively improves metabolic status in individuals with MetS, including blood glucose, lipid profile, obesity‐related indicators, insulin levels, and blood pressure. However, the overall literature quality is moderate to low. Further rigorous RCTs are needed to explore Baduanjin's effects on MetS, considering intervention methods, content, and research methodologies.","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"187 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139862833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
To explore the pathogenesis and scientific connotation of non-alcoholic fatty liver based on the theory of turbid toxin of traditional Chinese medicine 以中医浊毒理论为基础,探讨非酒精性脂肪肝的发病机理及科学内涵
Pub Date : 2024-01-08 DOI: 10.1002/acm4.1
Guanjun Kou, Hongwei Luo, Xing Huang, Mingxue Bai, Ke Cao, Hongyu Ma, Xiang Lv

Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disease characterized by the accumulation of excessive liver lipids without alcohol-induced damage. It has emerged as a significant global health issue. A recent research has indicated that dysregulation of lipid decomposition, uptake, production, oxidation, and secretion causes alterations in various types of lipids, leading to organelle dysfunction and metabolic signaling pathway impairment. Scholars propose that turbid toxin is crucial in the pathogenesis of NAFLD. This article elucidates the meaning of turbid toxin in conjunction with the current literature and analyzes the modern pathophysiological mechanism underlying the development of NAFLD, including turbid toxic substance production, related organelle involvement, biological processes, and pathways, ultimately leading to disease outcomes. The relationship between traditional Chinese medicine and the turbid toxin is also explored to establish a foundation for further mechanistic research on NAFLD.

非酒精性脂肪肝(NAFLD)是一种代谢性肝病,其特点是肝脏脂质过多堆积,但没有酒精引起的损伤。它已成为一个重要的全球健康问题。最近的一项研究表明,脂质分解、摄取、生成、氧化和分泌失调会引起各类脂质的改变,从而导致细胞器功能障碍和代谢信号通路受损。有学者提出,浊毒素在非酒精性脂肪肝的发病机制中起着关键作用。本文结合现有文献阐明了浊毒的含义,并分析了非酒精性脂肪肝发病的现代病理生理机制,包括浊毒物质的产生、相关细胞器的参与、生物学过程和途径,最终导致疾病的结局。此外,还探讨了中药与浊毒的关系,为进一步开展非酒精性脂肪肝的机理研究奠定基础。
{"title":"To explore the pathogenesis and scientific connotation of non-alcoholic fatty liver based on the theory of turbid toxin of traditional Chinese medicine","authors":"Guanjun Kou,&nbsp;Hongwei Luo,&nbsp;Xing Huang,&nbsp;Mingxue Bai,&nbsp;Ke Cao,&nbsp;Hongyu Ma,&nbsp;Xiang Lv","doi":"10.1002/acm4.1","DOIUrl":"10.1002/acm4.1","url":null,"abstract":"<p>Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disease characterized by the accumulation of excessive liver lipids without alcohol-induced damage. It has emerged as a significant global health issue. A recent research has indicated that dysregulation of lipid decomposition, uptake, production, oxidation, and secretion causes alterations in various types of lipids, leading to organelle dysfunction and metabolic signaling pathway impairment. Scholars propose that turbid toxin is crucial in the pathogenesis of NAFLD. This article elucidates the meaning of turbid toxin in conjunction with the current literature and analyzes the modern pathophysiological mechanism underlying the development of NAFLD, including turbid toxic substance production, related organelle involvement, biological processes, and pathways, ultimately leading to disease outcomes. The relationship between traditional Chinese medicine and the turbid toxin is also explored to establish a foundation for further mechanistic research on NAFLD.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"40-51"},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139445351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advanced Chinese Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1